Immunogenicity and safety of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) in South African children.
Mphahlele
M J
MJ
Burnett
R J
RJ
Kyaw
T
T
Schoeman
H S
HS
Aspinall
S
S
D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D008297:Male; D013019:South Africa; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; C115360:heberbiovac-HB